BEAM Stock Analysis: Beam Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.654m USD | 12M Return: -1% | US07373V1052 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 46.1M
Qual. Beats: -1
Rev. Trend: -34.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 6.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Beam Therapeutics Inc. is a US-based biotechnology company developing precision genetic medicines for serious diseases, with a pipeline spanning sickle cell disease, alpha-1 antitrypsin deficiency, phenylketonuria, and glycogen storage disease type 1a. The company employs both ex vivo approaches, such as its patient-specific HSC therapy ristoglogene autogetemcel, and in vivo approaches, using lipid nanoparticle (LNP) formulations to deliver genetic medicines to the liver.
A core element of Beams strategy is base editing, a gene-editing modality that chemically converts one DNA base pair to another without cutting the double helix. The company complements this with the ESCAPE platform, which pairs multiplex base editing of hematopoietic stem cells with antibody-based conditioning, supported by its anti-CD117 monoclonal antibody (BEAM-103) designed to enable that conditioning process.
Beam has research collaborations with Pfizer (in vivo base editing programs for rare genetic diseases of the liver, muscle, and central nervous system), Verve Therapeutics (cardiovascular disease), and Orbital Therapeutics (RNA design). Founded in 2017 and headquartered in Cambridge, Massachusetts, the company listed on NASDAQ in 2020 and is classified within the Health Care sectors biotechnology sub-industry.
- Ristoglogene autogetemcel sickle cell trial data readout approaches
- Pfizer collaboration milestone payments offset operating cash burn
- Competition from Vertex Casgevy pressures sickle cell market share
| Net Income: -85.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.06 > 0.02 and ΔFCF/TA 12.74 > 1.0 |
| NWC/Revenue: 703.5% < 20% (prev 1.66k%; Δ -957.9% < -1%) |
| CFO/TA -0.26 > 3% & CFO -359.4m > Net Income -85.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 14.57 > 1.5 & < 3 |
| Outstanding Shares: last quarter (104.3m) vs 12m ago 2.29% < -2% |
| Gross Margin: 85.71% > 18% (prev -557.5%; Δ 643.2% > 0.5%) |
| Asset Turnover: 11.24% > 50% (prev 4.33%; Δ 6.90% > 0%) |
| Interest Coverage Ratio: -2.20 > 6 (EBIT TTM -85.4m / Interest Expense TTM 38.9m) |
| A: 0.79 (Total Current Assets 1.18b - Total Current Liabilities 80.9m) / Total Assets 1.39b |
| B: -1.34 (Retained Earnings -1.86b / Total Assets 1.39b) |
| C: -0.06 (EBIT TTM -85.4m / Avg Total Assets 1.39b) |
| D: 3.34 (Book Value of Equity 1.07b / Total Liabilities 319.2m) |
| Altman-Z'' = 3.92 = AA |
As of October 13, 2026, the stock is trading at USD 25.13 with a total of 1,412,746 shares traded. Over the past week, the price has changed by -2.10%, over one month by +4.19%, over three months by -18.94% and over the past year by -1.02%.
Current recommended Stop Loss: 23.40 (which is 6.9% or 1.2 ATR below the current price).
Beam Therapeutics has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy BEAM.
- StrongBuy: 12
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 52.2 | 107.5% |
P/S = 17.0122
P/B = 2.3571
Revenue TTM = 156.0m USD
EBIT TTM = -85.4m USD
EBITDA TTM = -63.2m USD
Long Term Debt = 100.3m USD (from longTermDebt, last quarter)
Short Term Debt = 15.2m USD (from shortTermDebt, last quarter)
Debt = 394.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 147.1m
Net Debt = -758.5m USD (calculated: Debt 394.5m - CCE 1.15b)
Enterprise Value = 1.90b USD (2.65b + Debt 394.5m - CCE 1.15b)
Interest Coverage Ratio = -2.20 (Ebit TTM -85.4m / Interest Expense TTM 38.9m)
EV/FCF = -21.23x (Enterprise Value 1.90b / FCF TTM -89.3m)
FCF Yield = -4.71% (FCF TTM -89.3m / Enterprise Value 1.90b)
FCF Margin = -57.23% (FCF TTM -89.3m / Revenue TTM 156.0m)
Net Margin = -54.75% (Net Income TTM -85.4m / Revenue TTM 156.0m)
Gross Margin = 85.71% ((Revenue TTM 156.0m - Cost of Revenue TTM 22.3m) / Revenue TTM)
Gross Margin QoQ = none% (prev 65.16%)
Tobins Q-Ratio = 1.37 (Enterprise Value 1.90b / Total Assets 1.39b)
Interest Expense / Debt = 9.86% (Interest Expense 38.9m / Debt 394.5m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -67.5m (EBIT -85.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.54 (Total Current Assets 1.18b / Total Current Liabilities 94.0m)
Debt / Equity = 0.37 (Debt 394.5m / totalStockholderEquity, last quarter 1.07b)
Debt / EBITDA = 12.00 (negative EBITDA) (Net Debt -758.5m / EBITDA -63.2m)
Debt / FCF = 8.49 (negative FCF - burning cash) (Net Debt -758.5m / FCF TTM -89.3m)
Total Stockholder Equity = 1.11b (last 4 quarters mean from totalStockholderEquity)
RoA = -6.15% (Net Income -85.4m / Total Assets 1.39b)
RoE = -7.70% (Net Income TTM -85.4m / Total Stockholder Equity 1.11b)
RoCE = -7.06% (EBIT -85.4m / Capital Employed (Equity 1.11b + L.T.Debt 100.3m))
RoIC = -5.14% (negative operating profit) (NOPAT -67.5m / Invested Capital 1.31b)
WACC = 13.14% (E(2.65b)/V(3.05b) * Re(13.93%) + D(394.5m)/V(3.05b) * Rd(9.86%) * (1-Tc(0.21)))
Discount Rate = 13.93% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 91.99 | Cagr: 11.48%
[DCF] Fair Price = unknown (Cash Flow -89.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.86 | # QB: -1
Revenue Correlation: -34.73 | Revenue CAGR: -25.98% | SUE: -0.46 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-1.17 | Chg30d=+0.00% | Revisions=-8% | Analysts=13
EPS current Year (2026-12-31): EPS=-4.45 | Chg30d=+0.00% | Revisions=-8% | GrowthEPS=-449.8% | GrowthRev=-65.2%
EPS next Year (2027-12-31): EPS=-4.74 | Chg30d=+0.00% | Revisions=+18% | GrowthEPS=-6.5% | GrowthRev=+29.2%
[Analyst] Revisions Ratio: +0% (up=13, down=13)